Given the premium that Novo Nordisk (NVO)
enjoys for its very strong position within diabetes care, you might
think that a company with strong positions in two significant
pharmaceutical areas would enjoy an even bigger premium. That's not the
case for Shire (SHPG),
though, and investors may have an opportunity here to take advantage of
one of the few bargains in the pharma space. Moreover, with Big Pharma
likely on the prowl for add-on deals, Shire's relative value may make it
an appealing target.
Please continue reading here:
If Investors Won't Buy Shire, Big Pharma Should
No comments:
Post a Comment